Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
PR Newswire•06/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.